Category

Archives

Histone Demethylase

Evaluation of Histone Demethylase Inhibitor ML324 and Acyclovir against Cyprinid herpesvirus 3 Infection

0 views | Jan 03 2024

ML324 demonstrates significant potential as an effective treatment against Cyprinid herpesvirus 3 (CyHV-3) infection in koi fish, outperforming traditional antiviral drugs like acyclovir in inhibiting virus replication both in vitro and in vivo. [Read the Full Post]

Research update and opportunity of non-hormonal male contraception: Histone demethylase KDM5B-based targeting

36 views | Dec 27 2023

In exploring non-hormonal male contraceptives, leveraging in-silico studies of tissue-specific targets and small-molecule candidates presents a promising avenue, albeit with hurdles, toward potentially transformative developments in contraceptive options. [Read the Full Post]

Effect of feed enriched by products formulated from coconut water, palm sap sugar, and mushroom on the chemical composition of feed and carcass, growth performance, body indices, and gut micromorphology of giant gourami, Osphronemus goramy (Lacepède, 1801), juveniles

66 views | Dec 05 2023

The study found that the formulation KP3, incorporating palm sap sugar, coconut water, and specific microorganisms, significantly improved the nutrition, growth, and body composition of giant gourami juveniles, making it a promising option for aquaculture in Indonesia. [Read the Full Post]

ALKBH5 causes retinal pigment epithelium anomalies and choroidal neovascularization in age-related macular degeneration via the AKT/mTOR pathway

67 views | Dec 02 2023

ALKBH5 upregulation in age-related macular degeneration leads to retinal pigment epithelium dysfunction and choroidal neovascularization through its demethylation activity, activating the PIK3C2B-mediated AKT/mTOR pathway, and pharmacological inhibitors like IOX1 offer potential therapeutic interventions. [Read the Full Post]

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma

97 views | Nov 20 2023

The study demonstrates that inhibiting lysine-specific demethylase 1 (LSD1) synergizes with proteasome inhibitors, such as carfilzomib, overcoming drug resistance in multiple myeloma and other B-cell malignancies, offering a promising therapeutic strategy. [Read the Full Post]

Evaluation of Histone Demethylase Inhibitor ML324 and Acyclovir against Cyprinid herpesvirus 3 Infection

149 views | Nov 16 2023

ML324, a specific inhibitor of JMJD2 histone demethylase, has demonstrated promising potential as a treatment against CyHV-3 infection in koi fish, effectively inhibiting viral replication both in vitro and in vivo. [Read the Full Post]

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials

0 views | Jun 29 2023

This review summarizes the structure and functions of LSD1, its role in cancer and non-cancer diseases, and the potential of covalent and non-covalent LSD1 inhibitors, including those in clinical trials, as potent and selective anticancer agents. [Read the Full Post]

The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

208 views | Jun 29 2023

The chromatin kinase VRK1 regulates the epigenetic patterns of histone H3 acetylation and methylation, particularly at lysines 4, 9, and 27, and is essential for coordinating chromatin organization and nuclear functions. [Read the Full Post]

JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL

0 views | Jun 22 2023

The combination of a LSD1 inhibitor with a JAK/STAT pathway inhibitor or a BCL2 inhibitor reverses resistance and efficiently inhibits the growth of ETP-ALL cells, suggesting a potential novel combination therapy for ETP-ALL patients. [Read the Full Post]

GSK-J1-loaded, hyaluronic acid-decorated metal-organic frameworks for the treatment of ovarian cancer

131 views | Jun 17 2023

The study demonstrates the potential of hyaluronic acid-decorated metal-organic frameworks delivering the JMJD3 demethylase inhibitor GSK-J1 (HA@MOF@GSK-J1) as an effective and targeted strategy for treating carboplatin-resistant ovarian cancer. [Read the Full Post]